Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Paeds Vivasgenetics-dysmorphology-and-metabolism

Paeds Vivas · genetics-dysmorphology-and-metabolism

Fragile X syndrome — branching viva

Branching viva on fragile X syndrome: recognising the indication to test, explaining the FMR1 CGG-repeat expansion and FMRP loss, confirming the molecular diagnosis with PCR plus methylation analysis, classifying the allele, building comorbidity-driven support, and running cascade testing with premutation surveillance.

branching clinical structured oral3 min readVerification in progress

Target exams

RACP DCEMRCPCH ClinicalRCPSC Pediatrics
On this page
Study tools

Target exams

RACP DCEMRCPCH ClinicalRCPSC Pediatrics
Prompt
Outpatient clinic: a three-year-old boy with global developmental delay and autistic features, a maternal uncle with intellectual disability, and a previously normal chromosomal microarray. The examiner asks: why does the normal microarray not exclude fragile X, what is the two-part molecular test, how do you classify the FMR1 allele, what is the pathophysiology of FMRP loss, and what is the management framework — then branches to his mother, found to carry a premutation of 110 repeats, and asks you to explain the maternal-expansion rule, the premutation-associated conditions, and the cascade-testing obligation to the wider family.

Opening framework

My framework has four layers. First, the indication — any child with unexplained intellectual disability or developmental delay, especially a boy, and any child with autism and intellectual involvement, warrants fragile X testing. Second, the investigation — a two-part molecular assay of FMR1 PCR plus methylation analysis, because karyotype and microarray miss the repeat expansion. Third, the mechanism — a CGG-repeat expansion that methylates and silences FMR1, abolishing FMRP, the synaptic translational brake. Fourth, the family — cascade testing of the mother, siblings, and at-risk relatives, with premutation surveillance. [1]

Paediatrics Fellowship Pro

Continue reading

You have read the opening of this viva. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship library.

Sign in to continueSee pricing
References5ShowHide
  1. [1]Hersh JH, Saul RA Health supervision for children with fragile X syndrome. Pediatrics, 2011.PMID 21518720
  2. [3]Santoro MR, Bray SM, Warren ST. Molecular mechanisms of fragile X syndrome: a twenty-year perspective. Annu Rev Pathol, 2012.PMID 22017584
  3. [5]Pirozzi F, Tabolacci E, Neri G. The FRAXopathies: definition, overview, and update. Am J Med Genet A, 2011.PMID 21739597
  4. [6]Protic D, et al. New targeted treatments for fragile X syndrome. Curr Pediatr Rev, 2019.PMID 31241016
  5. [9]Hagerman R, et al. Insight and recommendations for fragile X-premutation-associated conditions from the Fifth International Conference. Cells, 2023.PMID 37759552
Paediatrics Fellowship Pro

$29/ monthor $279 / year

The complete Paediatrics Fellowship library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousFatty-acid oxidation disorders — branching vivagenetics-dysmorphology-and-metabolismNextGenetic deafness and blindness syndromes — branching vivagenetics-dysmorphology-and-metabolism